Pioglitazone and Rosiglitazone: Effects of Treatment with a Thiazolidinedione on Lipids and Non Conventional Cardiovascular Risk Factors

Publisher： Bentham Science Publishers

E-ISSN： 2212-3938|3|2|77-84

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.3, Iss.2, 2008-05, pp. : 77-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-term Effect of Glimepiride and Rosiglitazone on Non-conventional Cardiovascular Risk Factors in Metformin-treated Patients Affected by Metabolic Syndrome: a Randomized, Double-blind Clinical Trial

By Derosa G   Gaddi AV   Ciccarelli L   Fogari E   Ghelfi M   Cicero AFG  

The Journal of International Medical Research, Vol. 33, Iss. 3, 2005-05 ,pp. : 284-294

Field House Publishing

Access to resources Recommend Favorite

Thiazolidinedione treatment is not associated with an increased risk of major adverse cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1643, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Treatment of Cardiovascular Risk Factors in Women

By  

Current Medicinal Chemistry, Vol. 22, Iss. 31, 2015-10 ,pp. : 3580-3596

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of the Thiazolidinediones on Cardiovascular Risk Factors

By Gilling L.   Suwattee P.   DeSouza C.   Asnani S.   Fonseca V.  

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 3, 2002-01 ,pp. : 149-156

Adis International

Access to resources Recommend Favorite

Pioglitazone, rosiglitazone face up to MI, HF risk analyses

By  

Reactions Weekly, Vol. 1, Iss. 1170, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite